GE HealthCare Raises Full-Year EPS Outlook After Q3 Beat, Shares Jump 8%
GEHC sits 31% above its 52-week low of $58.75.
Summary
GE HealthCare beat Q3 estimates with adjusted EPS of $1.34 versus $1.20 consensus and revenue of $5.513 billion, ahead of the $5.35 billion expected. The company raised FY2026 adjusted EPS guidance to $4.95-$5.05 from $4.80-$5.00 and now sees organic revenue growth of about 4%, up from 3%-4%, with adjusted EBIT margin of 15.5%-15.7%. Orders grew 4.0% organically with a book-to-bill of 1.03x and a $23.7 billion backlog; Pharmaceutical Diagnostics revenue rose 13.8% to $846 million. Margin headwinds remain from memory chip inflation and higher oil prices in the supply chain, partly offset by lower tariff expense. Shares were up 8.17% at $76.92 on Wednesday.
At the time of this announcement, GEHC was trading at $76.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.7B. The 52-week trading range was $58.75 to $89.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.